BI 2536

Name: BI 2536
Brand: Selleck Chemicals
SKU: S1109
Rating: 5 (162 reviews)

For research use only.

Catalog No.S1109

162 publications

Molecular Weight(MW): 521.66

BI-2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. BI-2536 inhibits Bromodomain 4 (BRD4) with Kd of 37 nM and potently suppresses c-Myc expression. BI-2536 induces apoptosis and attenuates autophagy. Phase 2.

Selleck's BI 2536 has been cited by 162 publications

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Science, 2015, 13;347(6227):aaa2630.

PubMed: 25636800 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 11;147(4):853-67.

PubMed: 22078882 ( click the link to review the publication )

Cancer Cell, 2010, 18(6):641-54

PubMed: 21156286 ( click the link to review the publication )

Mol Cell, 2020, 10.1016/j.molcel.2020.01.023

PubMed: 32035037 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6):e201910019

PubMed: 32271878 ( click the link to review the publication )

Cell Rep, 2020, 17;30(11):3605-3615.e5

PubMed: 32187533 ( click the link to review the publication )

Cell Death Differ, 2020, 19

PubMed: 32203171 ( click the link to review the publication )

Oncogene, 2020, 39(15):3145-3162

PubMed: 32060423 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(3):350-362

PubMed: 32017920 ( click the link to review the publication )

ACS Chem Biol, 2020, 20;15(3):669-674

PubMed: 32004428 ( click the link to review the publication )

J Cell Sci, 2020, 2;jcs.244442

PubMed: 32487663 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(4):833-839

PubMed: 31708096 ( click the link to review the publication )

DNA Cell Biol, 2020, 10.1089/dna.2019.5002

PubMed: 32182129 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31947732 ( click the link to review the publication )

J Cancer, 2020, 11(11):3274-3287

PubMed: 32231733 ( click the link to review the publication )
Neuroreport, 2020, 31(11):787-797

PubMed: 32568772 ( click the link to review the publication )

Cell Res, 2019, 29(7):562-578

PubMed: 31201382 ( click the link to review the publication )

Mol Cell, 2019, 73(5):915-929

PubMed: 30849395 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3779

PubMed: 31439829 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846375

PubMed: 31156720 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1615-1627

PubMed: 31227645 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Mol Cancer Res, 2019, doi: 10

PubMed: 31604847 ( click the link to review the publication )

Lab Invest, 2019, 99(9):1275-1286

PubMed: 30996295 ( click the link to review the publication )

Open Biol, 2019, 9(8):190136

PubMed: 31455158 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Cancer Res, 2018, 78(2):572-583

PubMed: 29180474 ( click the link to review the publication )

Elife, 2018, 7:e36739

PubMed: 29897330 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )
Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Hum Gene Ther, 2018, 29(8):886-901

PubMed: 29641320 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Cell Signal, 2018, 52:137-146

PubMed: 30223016 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

J Oncol, 2018, 2018:3979527

PubMed: 30631355 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

Cell Res, 2017, 27(2):274-293

PubMed: 27958289 ( click the link to review the publication )

Mol Cell, 2017, 67(4):579-593

PubMed: 28781233 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1506

PubMed: 29138396 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28994651 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(8):1017-1028

PubMed: 28807782 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Curr Biol, 2017, 27(10):1477-1484

PubMed: 28479321 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )
FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )

Oncotarget, 2017, 9(13):10920-10933

PubMed: 29541386 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(6):411-8

PubMed: 27043190 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):48-59

PubMed: 26586723 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )
Nat Cell Biol, 2015, 17(8):1024-35

PubMed: 26192437 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Nat Commun, 2015, 6:8077

PubMed: 26293378 ( click the link to review the publication )

Nat Commun, 2015, 6:6946

PubMed: 25897860 ( click the link to review the publication )

Nat Commun, 2015, 6:10076

PubMed: 26647647 ( click the link to review the publication )

Nat Commun, 2015, 6:10072

PubMed: 26656453 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29617-28

PubMed: 26468278 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(33):34475-93

PubMed: 26439686 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(6):538-49

PubMed: 24776885 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )
Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Dev Cell, 2013, 25(6):555-71

PubMed: 23769972 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Biol Chem, 2013, 288(33):23765-75

PubMed: 23814058 ( click the link to review the publication )
J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description

Features

The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Targets

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. ^[1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rR[2lEPTB;MD6wNFc4PiEQvF2=	MkXEV2FPT0WU
ACN	M4PDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDKN4VKSzVyPUCuNFA5PDNizszN	MWHTRW5ITVJ?
TE-8	NIq0RoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlj1TWM2OD1yLkCwPVQyKM7:TR?=	M3PlSXNCVkeHUh?=
LC-2-ad	M3nkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jjRWlEPTB;MD6wNVA6OyEQvF2=	MnftV2FPT0WU
ALL-PO	M3r4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXX3c4l6UUN3ME2wMlAyOyEQvF2=	NYHZZZg{W0GQR1XS
EW-16	NWjGN45yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTBwMEGzN\|Yh\|ryP	MXTTRW5ITVJ?
KM12	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zwcmlEPTB;MD6wNVM1QCEQvF2=	MVLTRW5ITVJ?
GI-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrpTWM2OD1yLkCxN\|g{KM7:TR?=	MUjTRW5ITVJ?
LS-411N	NGPJSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELBOYdKSzVyPUCuNFE1ODdizszN	MWfTRW5ITVJ?
ES8	NX\ZZXdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrDT4d2UUN3ME2wMlAyPDl2IN88US=>	MUHTRW5ITVJ?
SNU-C2B	MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTBwMEG1NlYh\|ryP	NHjaSWFUSU6JRWK=
CESS	M1HrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1S4OGlEPTB;MD6wNVYxOiEQvF2=	MlL3V2FPT0WU
697	NE\YOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\PcGlEPTB;MD6wNVY3QCEQvF2=	MU\TRW5ITVJ?
NCI-H1963	Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\jepdGUUN3ME2wMlAyPjd\|IN88US=>	MULTRW5ITVJ?
IA-LM	NHrWWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jYZmlEPTB;MD6wNVY5QCEQvF2=	MnfpV2FPT0WU
SW954	NEPpZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEK3V5ZKSzVyPUCuNFE4ODVizszN	NX2wWFhbW0GQR1XS
RL95-2	MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rCSWlEPTB;MD6wNVc{QCEQvF2=	NFnRNpFUSU6JRWK=
LXF-289	NXHCZZh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHm0SYRKSzVyPUCuNFE4PyEQvF2=	NVXaXpRWW0GQR1XS
OCUB-M	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PrOWlEPTB;MD6wNVgzPiEQvF2=	NHvreoFUSU6JRWK=
RKO	M3ryTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLvTWM2OD1yLkCxPVg4KM7:TR?=	NHPEOZNUSU6JRWK=
LOUCY	NUjOTHpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fw[GlEPTB;MD6wNlA2KM7:TR?=	NFriVnpUSU6JRWK=
NOS-1	M2n5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTBwMEKwPVMh\|ryP	Mn7KV2FPT0WU
A4-Fuk	NWPQWHdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3PTWM2OD1yLkCyNlE5KM7:TR?=	NH\6VolUSU6JRWK=
A388	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnubYZKSzVyPUCuNFIzOjdizszN	NHzRNHhUSU6JRWK=
TE-9	NIizfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrpN3l{UUN3ME2wMlAzOjZzIN88US=>	MmXxV2FPT0WU
KURAMOCHI	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUD2UI9SUUN3ME2wMlAzOjh3IN88US=>	M4TFZXNCVkeHUh?=
KALS-1	M{f5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzjTWM2OD1yLkCyN\|M5KM7:TR?=	Mk\nV2FPT0WU
HOP-62	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHGTWM2OD1yLkCyOFIh\|ryP	NWPpSXh4W0GQR1XS
RPMI-8402	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLlO3lKSzVyPUCuNFI2ODhizszN	MlXMV2FPT0WU
TE-1	NWn6e2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M12yd2lEPTB;MD6wNlUyOiEQvF2=	NVnMUI1rW0GQR1XS
CCRF-CEM	NIjqO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTBwMEK1OFMh\|ryP	MmfpV2FPT0WU
HUTU-80	NFLHdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1izU2lEPTB;MD6wNlYzPCEQvF2=	MYfTRW5ITVJ?
NCI-H1648	NH:2XWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\ITWM2OD1yLkCyOlQ4KM7:TR?=	MVfTRW5ITVJ?
HCE-4	M{nZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2SweGlEPTB;MD6wNlY5OiEQvF2=	MUXTRW5ITVJ?
ETK-1	NH3aUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mln2TWM2OD1yLkCyO\|M3KM7:TR?=	M1zBTnNCVkeHUh?=
TE-15	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPWTWM2OD1yLkCyO\|M5KM7:TR?=	MmTFV2FPT0WU
BE-13	Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPx[WVKSzVyPUCuNFI4PCEQvF2=	MnnsV2FPT0WU
KE-37	M4T5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P6NGlEPTB;MD6wNlc1OSEQvF2=	MXTTRW5ITVJ?
NCI-H1355	NGW1V3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{SxfWlEPTB;MD6wNlc5OyEQvF2=	M2TLUnNCVkeHUh?=
TE-11	NVnrR5dJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUCxPYFxUUN3ME2wMlAzQDB7IN88US=>	M{DBW3NCVkeHUh?=
BL-70	M4nWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\qXXhEUUN3ME2wMlAzQDV5IN88US=>	MYfTRW5ITVJ?
ES6	NXvjXplwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTBwMEK4PFEh\|ryP	MlT0V2FPT0WU
GT3TKB	NIHNeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGeyd5lKSzVyPUCuNFI6PTNizszN	MYTTRW5ITVJ?
LB647-SCLC	NIfHflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTBwMEOxPVUh\|ryP	M{P2SXNCVkeHUh?=
NB13	NV7CXW1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;VR2lEPTB;MD6wN\|MyPiEQvF2=	NInZeoFUSU6JRWK=
ST486	NYXZUml2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjnTWM2OD1yLkCzN\|M4KM7:TR?=	NUPYTnpMW0GQR1XS
NCI-H82	M2X6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTBwMEOzOFMh\|ryP	M{HXNXNCVkeHUh?=
NTERA-S-cl-D1	NFTUdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILPTo9KSzVyPUCuNFM{QTlizszN	M4PTTXNCVkeHUh?=
ES4	NXTSco1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPaOndKSzVyPUCuNFM1PjNizszN	NUfwTnpjW0GQR1XS
SK-NEP-1	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4j5UmlEPTB;MD6wN\|Q6QSEQvF2=	MUjTRW5ITVJ?
Becker	NYDsXlBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTBwMEO1OVUh\|ryP	MnjaV2FPT0WU
A101D	NELZU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jPN2lEPTB;MD6wN\|c1QCEQvF2=	M{fuTnNCVkeHUh?=
SK-UT-1	M2LvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn32TWM2OD1yLkCzO\|c1KM7:TR?=	Ml\tV2FPT0WU
SW982	NXjpdY9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vLVmlEPTB;MD6wN\|c6KM7:TR?=	NWXSb\|dQW0GQR1XS
TE-10	M4rVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7wTWM2OD1yLkC0NFQ3KM7:TR?=	NH7w[GtUSU6JRWK=
OVCAR-4	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXabpVKSzVyPUCuNFQxPTlizszN	MV;TRW5ITVJ?
KP-N-YS	NWe4bHV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1P0RmlEPTB;MD6wOFA5PSEQvF2=	NUPTXpdQW0GQR1XS
BL-41	NXnvWFhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fqT2lEPTB;MD6wOFEzPSEQvF2=	NVjrSJp2W0GQR1XS
MZ1-PC	NEH1R\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIGxcWhKSzVyPUCuNFQyOjdizszN	M4XUXHNCVkeHUh?=
PF-382	NHX0SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HQWmlEPTB;MD6wOFE6QCEQvF2=	M3fqW3NCVkeHUh?=
MOLT-13	NHTOPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTBwMESyN\|gh\|ryP	MVTTRW5ITVJ?
HCC1599	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\uTWM2OD1yLkC0NlU5KM7:TR?=	NHX1V\|VUSU6JRWK=
IST-MEL1	MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;XSolDUUN3ME2wMlA1PDR{IN88US=>	NVTBdHNNW0GQR1XS
LU-139	NYTkfWZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlH1TWM2OD1yLkC0OFQzKM7:TR?=	NVuwUlBoW0GQR1XS
MS-1	M2rMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXWwemh4UUN3ME2wMlA1PzBzIN88US=>	MkC4V2FPT0WU
MFH-ino	NITrcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DjPGlEPTB;MD6wOVAxOyEQvF2=	M13TVHNCVkeHUh?=
IMR-5	NVrkOGxXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwMEWwNlEh\|ryP	NYjqXo5MW0GQR1XS
TE-5	NHrTXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFn3VnBKSzVyPUCuNFUxPjNizszN	MnXWV2FPT0WU
DJM-1	NISwWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVSxT3hTUUN3ME2wMlA2OTR{IN88US=>	NYPWUpF4W0GQR1XS
NB17	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfXdnJKSzVyPUCuNFUzODdizszN	NYX2bHY6W0GQR1XS
KARPAS-45	NHyxXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHqVnFMUUN3ME2wMlA2OzV6IN88US=>	NEjoe5VUSU6JRWK=
TGBC1TKB	Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXaTWM2OD1yLkC1OFA2KM7:TR?=	NV3W[JA4W0GQR1XS
ML-2	NHu3emlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDWZ2t7UUN3ME2wMlA2PDF2IN88US=>	MU\TRW5ITVJ?
no-10	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjZZ5RKSzVyPUCuNFU1PzRizszN	MU\TRW5ITVJ?
CTV-1	M2jnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUWydHI3UUN3ME2wMlA2PTB{IN88US=>	Ml;xV2FPT0WU
SJSA-1	NGOzblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;COGlEPTB;MD6wOVUzKM7:TR?=	NV\LOZBtW0GQR1XS
HC-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHsW4tKSzVyPUCuNFU2QTdizszN	NEHxZpFUSU6JRWK=
TE-12	NUnxZ45JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3T4dGlEPTB;MD6wOVYyOyEQvF2=	M3fyUXNCVkeHUh?=
KY821	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XBN2lEPTB;MD6wOVY{OiEQvF2=	M{fXR3NCVkeHUh?=
TALL-1	NHr0bnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXS4S\|l3UUN3ME2wMlA2PzB6IN88US=>	MUnTRW5ITVJ?
DEL	NXfHT4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrXTWM2OD1yLkC1O\|A6KM7:TR?=	NV3WSFI4W0GQR1XS
TE-6	NYDGfmRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmT5TWM2OD1yLkC1O\|IzKM7:TR?=	MWfTRW5ITVJ?
SK-LMS-1	NHO4PW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwMEW4NFUh\|ryP	MXzTRW5ITVJ?
EW-1	M{PJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn65TWM2OD1yLkC1PFM4KM7:TR?=	MonmV2FPT0WU
8-MG-BA	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HvfmlEPTB;MD6wOVg2OSEQvF2=	NUH2SlVMW0GQR1XS
NALM-6	M1;JOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLuTWM2OD1yLkC1PVc{KM7:TR?=	NV\uXpc2W0GQR1XS
LB771-HNC	NFXSVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zpeWlEPTB;MD6wOVk4QSEQvF2=	NECwVIdUSU6JRWK=
HT-144	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTBwME[xN{DPxE1?	NHvIXYRUSU6JRWK=
KM-H2	NX\ubJFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITFdoRKSzVyPUCuNFYzOjFizszN	NYHab\|JHW0GQR1XS
SF268	MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTBwME[yPFYh\|ryP	NF3Sb5ZUSU6JRWK=
RS4-11	NFrCeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzIW2lKSzVyPUCuNFY{ODRizszN	M3;mNnNCVkeHUh?=
MHH-PREB-1	NWPWelJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXqTWM2OD1yLkC2N\|E6KM7:TR?=	MVTTRW5ITVJ?
ATN-1	Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfITWM2OD1yLkC2N\|Q2KM7:TR?=	MnuyV2FPT0WU
BB30-HNC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTBwME[0N\|Yh\|ryP	NXi1R5JGW0GQR1XS
CPC-N	M2LJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPJfIRKSzVyPUCuNFY2OjRizszN	NXvzelc6W0GQR1XS
NB1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrUTWM2OD1yLkC2OlE{KM7:TR?=	M4XwS3NCVkeHUh?=
KS-1	M2j0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nGT2lEPTB;MD6wOlc1QCEQvF2=	NGrTSGdUSU6JRWK=
RXF393	M{PXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnTTWM2OD1yLkC2O\|Y1KM7:TR?=	M{HldnNCVkeHUh?=
IST-SL2	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTBwMEewNFQh\|ryP	MlT2V2FPT0WU
GI-ME-N	NFyxboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTBwMEeyPFYh\|ryP	NVvq[5RiW0GQR1XS
VA-ES-BJ	M{DKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTBwMEe0O\|Uh\|ryP	MnjyV2FPT0WU
NCI-H1581	NV3OVYNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTBwMEe0O\|gh\|ryP	M17BWXNCVkeHUh?=
U-266	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLNd4hQUUN3ME2wMlA4PDl5IN88US=>	NGOyW3dUSU6JRWK=
DMS-114	M4\GOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NES4NJVKSzVyPUCuNFc2OjhizszN	Mk\DV2FPT0WU
NCI-H187	NF3oXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTBwMEe3NlYh\|ryP	NVnaWlZPW0GQR1XS
SW962	NIq3cVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzHTWM2OD1yLkC3PFM6KM7:TR?=	NYDWTIF{W0GQR1XS
MONO-MAC-6	M1fQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HyOWlEPTB;MD6wO\|k5PiEQvF2=	MnnwV2FPT0WU
MOLT-16	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzuXZpKSzVyPUCuNFgyOjFizszN	NHq0fGtUSU6JRWK=
KNS-42	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUCyXXg{UUN3ME2wMlA5OTZzIN88US=>	NWH5T2RrW0GQR1XS
CMK	NHz0PZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojQTWM2OD1yLkC4NlI2KM7:TR?=	NFSxbXlUSU6JRWK=
Ramos-2G6-4C10	M4nBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXkWYdLUUN3ME2wMlA5OjJ3IN88US=>	M{fmSnNCVkeHUh?=
Daudi	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTBwMEiyOVYh\|ryP	NV;KZ4VwW0GQR1XS
NCI-H510A	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoT4TWM2OD1yLkC4N\|M3KM7:TR?=	MmnoV2FPT0WU
LB831-BLC	NIXkZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;5fJdKSzVyPUCuNFg2PjFizszN	M2LXU3NCVkeHUh?=
HEL	M{fYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULHXo04UUN3ME2wMlA5PjZ6IN88US=>	MWTTRW5ITVJ?
LU-134-A	NEXqSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvkXWdKSzVyPUCuNFg4ODhizszN	NWL3Sld5W0GQR1XS
NCI-H1694	M3HHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTBwMEi3OFQh\|ryP	NXzjS4hsW0GQR1XS
KGN	M{n4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXeyS2xNUUN3ME2wMlA5PzV7IN88US=>	MWPTRW5ITVJ?
A253	M2PHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWqzS4tLUUN3ME2wMlA5QDJ{IN88US=>	M2jZbHNCVkeHUh?=
DG-75	NWrsVnU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPTTWM2OD1yLkC4PVIzKM7:TR?=	NYi2em9jW0GQR1XS
MOLT-4	M{O5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwMEi5PFMh\|ryP	NVjxZnh2W0GQR1XS
NCI-SNU-5	NWjaUmtMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHDe5ZbUUN3ME2wMlA6OjV6IN88US=>	Ml64V2FPT0WU
ONS-76	NYnFWph5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXiWpBKSzVyPUCuNFkzPzZizszN	M1XZOnNCVkeHUh?=
NCI-H446	M1:yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3QTWM2OD1yLkC5OFYzKM7:TR?=	M3;ub3NCVkeHUh?=
COR-L279	NHv6eJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjSWXZbUUN3ME2wMlA6PTV4IN88US=>	NEDDXopUSU6JRWK=
Calu-6	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTBwMEm1PVgh\|ryP	MoDPV2FPT0WU
BC-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLrbY1KSzVyPUCuNFk3PjJizszN	NX65UXJwW0GQR1XS
NCI-H2126	NEf2fGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTBwMEm3PVEh\|ryP	NH31OlhUSU6JRWK=
NCI-H1882	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwMEm4NFkh\|ryP	NHfxXmVUSU6JRWK=
BB65-RCC	M2H5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;sTWM2OD1yLkGwNlk1KM7:TR?=	NIKzcYFUSU6JRWK=
DU-4475	NYLrXGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojMTWM2OD1yLkGwOFA4KM7:TR?=	MVPTRW5ITVJ?
NCI-H526	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nrWmlEPTB;MD6xNFQ1KM7:TR?=	MVTTRW5ITVJ?
NEC8	M1f6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfBTWM2OD1yLkGwOVI2KM7:TR?=	M{TxPHNCVkeHUh?=
NCI-H1304	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7PTWM2OD1yLkGwOVk1KM7:TR?=	NFLYXplUSU6JRWK=
L-540	MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfZSJdHUUN3ME2wMlExPzB6IN88US=>	M4XGT3NCVkeHUh?=
NCI-SNU-16	NV;MXmJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwMUC3OFIh\|ryP	M2fjO3NCVkeHUh?=
HD-MY-Z	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTFTWM2OD1yLkGwPFU3KM7:TR?=	MWnTRW5ITVJ?
K-562	NF\0SohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjCVoxKSzVyPUCuNVA5PThizszN	MWXTRW5ITVJ?
JAR	MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M32yb2lEPTB;MD6xNFkzPSEQvF2=	MYjTRW5ITVJ?
MZ2-MEL	NVKxZ3o4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljaTWM2OD1yLkGxNFUh\|ryP	Mmn0V2FPT0WU
L-363	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTBwMUGwO\|kh\|ryP	NIHFcZNUSU6JRWK=
BV-173	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVf1dWZYUUN3ME2wMlEyOjR\|IN88US=>	NG\zSFZUSU6JRWK=
NCI-H524	NETYTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXsOVlKSzVyPUCuNVEzPzRizszN	MXPTRW5ITVJ?
EoL-1-cell	NYHITGVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIj3d5lKSzVyPUCuNVE3PzJizszN	NHW1OldUSU6JRWK=
K052	NELBWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1f5[WlEPTB;MD6xNVcyOiEQvF2=	MnfQV2FPT0WU
TK10	NXPXRo9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjHWYMzUUN3ME2wMlEyPzJ6IN88US=>	M1Pre3NCVkeHUh?=
KU812	M3;YZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nneGlEPTB;MD6xNlA1PCEQvF2=	M1zHN3NCVkeHUh?=
RPMI-8226	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnS0TWM2OD1yLkGyNFUzKM7:TR?=	NX3WdJN4W0GQR1XS
MZ7-mel	M3LKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIq4WphKSzVyPUCuNVIzOzdizszN	NEDMe5JUSU6JRWK=
SK-PN-DW	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\odI9KSzVyPUCuNVIzQDdizszN	NWjseYYxW0GQR1XS
SR	NYTIUIh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LIPWlEPTB;MD6xNlQ1OSEQvF2=	M1X3UHNCVkeHUh?=
RPMI-6666	NI\1PFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3pTWM2OD1yLkGyO\|Q{KM7:TR?=	MoDxV2FPT0WU
no-11	NH35fJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTsVmRKSzVyPUCuNVI5PjlizszN	MVjTRW5ITVJ?
EW-3	NX\nPFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHK[lNKSzVyPUCuNVI5QTNizszN	NY\XOZk6W0GQR1XS
LAMA-84	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTEcotKSzVyPUCuNVMyQDdizszN	NYXtRZBKW0GQR1XS
HT	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWT3OYFGUUN3ME2wMlE{PTd2IN88US=>	MUfTRW5ITVJ?
KP-N-RT-BM-1	NF;mVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPBPIFKSzVyPUCuNVM3OTJizszN	M{POdXNCVkeHUh?=
NCI-H747	NYDifokxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfDZ2dKSzVyPUCuNVM4KM7:TR?=	MXjTRW5ITVJ?
NCCIT	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;TUW9KSzVyPUCuNVM6OzlizszN	NYLleVVHW0GQR1XS
MLMA	NYG3fGdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGK5fmNKSzVyPUCuNVQyPjdizszN	NVTvN5NwW0GQR1XS
LP-1	NWi1cYFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XyTGlEPTB;MD6xOFI1KM7:TR?=	MUDTRW5ITVJ?
CAL-148	M4L3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HyPWlEPTB;MD6xOFQ5OyEQvF2=	NGfXe2xUSU6JRWK=
GB-1	NYjWXIFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTVTWM2OD1yLkG0OVI3KM7:TR?=	NXrtR3RqW0GQR1XS
COR-L88	M3Hk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrzTWM2OD1yLkG0PFAzKM7:TR?=	NXP4fYtsW0GQR1XS
NKM-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUH3Z2w2UUN3ME2wMlE1QTB4IN88US=>	MWDTRW5ITVJ?
NB5	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTBwMUW0OlIh\|ryP	NYnsdFU1W0GQR1XS
SH-4	NFTvWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLVVldKSzVyPUCuNVU1PjZizszN	NEL0WnVUSU6JRWK=
EM-2	NXzo[IJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTBwMUW0Olch\|ryP	MXvTRW5ITVJ?
TGBC24TKB	NU\pemFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LMXGlEPTB;MD6xOVY2QSEQvF2=	NInjPYtUSU6JRWK=
SCLC-21H	NEnqcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWW4RXU1UUN3ME2wMlE2PzB{IN88US=>	Mn3SV2FPT0WU
COLO-684	NYjQ[ZJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTBwMUW3NlEh\|ryP	MofuV2FPT0WU
KINGS-1	NYLpSlVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTBwMUW5NUDPxE1?	MVzTRW5ITVJ?
LS-123	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33hdWlEPTB;MD6xOVkyPyEQvF2=	M{j0SHNCVkeHUh?=
MC116	NV2yU\|J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHKwZm5KSzVyPUCuNVYyPThizszN	MlfTV2FPT0WU
SU-DHL-1	MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fFPGlEPTB;MD6xOlIxPiEQvF2=	MX3TRW5ITVJ?
NCI-H64	MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jCPGlEPTB;MD6xOlM1PyEQvF2=	MlToV2FPT0WU
HCE-T	Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTBwMU[1NFQh\|ryP	M1HyXXNCVkeHUh?=
LOXIMVI	MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjxZY5iUUN3ME2wMlE3QTR7IN88US=>	M4\VZnNCVkeHUh?=
ARH-77	NVnWNFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTDTWM2OD1yLkG3N\|c6KM7:TR?=	MoLUV2FPT0WU
DOHH-2	NYTlfGg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLBTIpNUUN3ME2wMlE4Pjd{IN88US=>	NEDYWmVUSU6JRWK=
COLO-320-HSR	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnnNWZbUUN3ME2wMlE5OTV2IN88US=>	NHnhdGJUSU6JRWK=
NB6	NVnJWWxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfWfplDUUN3ME2wMlE5PTZ4IN88US=>	NHvwb4dUSU6JRWK=
L-428	NIixRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTBwMUi4NVMh\|ryP	NVTlfoZmW0GQR1XS
SNB75	NES5bmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlG1TWM2OD1yLkG4PFI1KM7:TR?=	NHLmXHVUSU6JRWK=
NCI-H2141	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmX1TWM2OD1yLkG5NFEyKM7:TR?=	NXLYVGNNW0GQR1XS
KARPAS-299	Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Lx[2lEPTB;MD6xPVI1OSEQvF2=	M4PP[nNCVkeHUh?=
LC4-1	NHnyPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFexe2pKSzVyPUCuNVk2ODJizszN	MmTpV2FPT0WU
UACC-257	NWT1O3lsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;qbGpKSzVyPUCuNVk6PDdizszN	Mn\wV2FPT0WU
EVSA-T	NWCzWlcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{j5TWlEPTB;MD6yNFMyOiEQvF2=	NHHVeZBUSU6JRWK=
JiyoyeP-2003	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj6bIlKSzVyPUCuNlA1PzdizszN	M1vUV3NCVkeHUh?=
NCI-H720	NGe1fYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2SwSmlEPTB;MD6yNFUzPSEQvF2=	M4fib3NCVkeHUh?=
GAK	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETWZZlKSzVyPUCuNlEyQDlizszN	MWHTRW5ITVJ?
HH	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXHdYxnUUN3ME2wMlIyPDB3IN88US=>	NX[yVFVtW0GQR1XS
NCI-H1436	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfPPJNKSzVyPUCuNlE1PjRizszN	Mn7WV2FPT0WU
GR-ST	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVW5PVVDUUN3ME2wMlIyPDh6IN88US=>	Ml7FV2FPT0WU
BC-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTBwMkK2NVYh\|ryP	NHLzOYJUSU6JRWK=
SIG-M5	NIPaempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEKz[5ZKSzVyPUCuNlI4OjdizszN	NID1cFFUSU6JRWK=
NCI-H345	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH[4V3dKSzVyPUCuNlM5ODVizszN	NIPYTWdUSU6JRWK=
OPM-2	Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTBwMkO4PFIh\|ryP	M2jvO3NCVkeHUh?=
LB1047-RCC	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzTTo9KSzVyPUCuNlQ1OSEQvF2=	NXrZOZNuW0GQR1XS
CTB-1	Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PEOGlEPTB;MD6yOFQ6OyEQvF2=	NHzLSVRUSU6JRWK=
A3-KAW	NHrIfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnUSmcxUUN3ME2wMlI2OzRzIN88US=>	NWTTNZp{W0GQR1XS
SF126	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFn4[nFKSzVyPUCuNlU{QDNizszN	NXHGRVJqW0GQR1XS
KARPAS-422	MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTBwMkW0N\|Uh\|ryP	Mn7zV2FPT0WU
MEG-01	NITNWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTBwMkW2O\|Mh\|ryP	NI\tRlZUSU6JRWK=
NCI-H209	NEjDSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{e0dGlEPTB;MD6yOlM4PCEQvF2=	M2\5[3NCVkeHUh?=
SBC-1	NVzxOmpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\EfWlEPTB;MD6yOlUh\|ryP	MnzEV2FPT0WU
K5	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTBwMk[5PFQh\|ryP	MYnTRW5ITVJ?
QIMR-WIL	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v5XGlEPTB;MD6yO\|E2PSEQvF2=	NILwR3pUSU6JRWK=
NMC-G1	NF;TcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7ZfVZCUUN3ME2wMlI5OjF5IN88US=>	MWrTRW5ITVJ?
IST-MES1	M1O2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\wT\|VKSzVyPUCuNlkzOzhizszN	NUDJWG05W0GQR1XS
SW684	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTBwM{CwOFch\|ryP	M{\pSXNCVkeHUh?=
MV-4-11	NUjXcVdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4H5c2lEPTB;MD6zNFc5QCEQvF2=	MlHpV2FPT0WU
LAN-6	NXHsNHlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTBwM{G1O\|Ih\|ryP	NVzGTWltW0GQR1XS
RH-1	M4XlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HkTmlEPTB;MD6zNVg4OSEQvF2=	M1LOOnNCVkeHUh?=
CP66-MEL	M3\xeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTBwM{G4O\|gh\|ryP	MVXTRW5ITVJ?
EC-GI-10	NETqZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Ppc2lEPTB;MD6zNlk5PyEQvF2=	MVrTRW5ITVJ?
GDM-1	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXPTWM2OD1yLkOzNFU6KM7:TR?=	M3nD[nNCVkeHUh?=
IST-SL1	NEflcmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTBwM{S5NVQh\|ryP	M33WN3NCVkeHUh?=
KMOE-2	NFvFfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnZXW01UUN3ME2wMlM2OTd3IN88US=>	NFPxSZdUSU6JRWK=
OS-RC-2	NUTPd\|dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\STWM2OD1yLkO1OVQ1KM7:TR?=	MoTrV2FPT0WU
HDLM-2	NWfyZWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTBwM{e4NVQh\|ryP	Mn\pV2FPT0WU
DSH1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17DdGlEPTB;MD6zPFY{OSEQvF2=	NFX6PZlUSU6JRWK=
LS-1034	NYPCV2pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTmSpBKSzVyPUCuN\|g6PTRizszN	Mk\iV2FPT0WU
LB373-MEL-D	NIHvOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXsTWM2OD1yLkO5NVk4KM7:TR?=	NV\0VFB7W0GQR1XS
GOTO	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYL1eox1UUN3ME2wMlQzOTF6IN88US=>	NI\mOHVUSU6JRWK=
MRK-nu-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHKTWM2OD1yLkSyNlA2KM7:TR?=	MkDFV2FPT0WU
SK-MM-2	M170TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rSSWlEPTB;MD60N\|Q1OiEQvF2=	M3\Fd3NCVkeHUh?=
BOKU	NYO3T5N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFP2OIFKSzVyPUCuOFM4QTJizszN	NGjCT\|RUSU6JRWK=
NOMO-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\kT3l{UUN3ME2wMlQ{QDZizszN	Mn3YV2FPT0WU
J-RT3-T3-5	NUi3XpNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjHcnJkUUN3ME2wMlQ1QDd6IN88US=>	NVvPUlQ6W0GQR1XS
COLO-668	NHTSdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrMTWM2OD1yLkS1OlY5KM7:TR?=	MnvDV2FPT0WU
SF539	M1ftSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fV[GlEPTB;MD60PFY5PCEQvF2=	MXzTRW5ITVJ?
LB2518-MEL	M4m1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33UTmlEPTB;MD60PVcxOyEQvF2=	NVey[4p5W0GQR1XS
TE-441-T	NHvycXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3FWphmUUN3ME2wMlUxOTJizszN	M4PMSXNCVkeHUh?=
MDA-MB-134-VI	MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moq1TWM2OD1yLkWwPVIyKM7:TR?=	MlHWV2FPT0WU
SCC-3	NXHVbmI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nZRWlEPTB;MD61NVg4OyEQvF2=	M{\ZbnNCVkeHUh?=
KLE	MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojzTWM2OD1yLkWyNVcyKM7:TR?=	Ml;YV2FPT0WU
LB2241-RCC	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULnSpNYUUN3ME2wMlUzPTJ3IN88US=>	NEjIfZhUSU6JRWK=
NCI-H1417	NH;0OoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;1TWM2OD1yLkWzOFM2KM7:TR?=	NEOyO\|NUSU6JRWK=
NCI-H2081	M33pdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVL0b3E5UUN3ME2wMlU5PjFzIN88US=>	MX\TRW5ITVJ?
NCI-H1522	M{PXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrLd4x[UUN3ME2wMlU6Ozh\|IN88US=>	Mm\hV2FPT0WU
NCI-H889	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HJPWlEPTB;MD61PVg1PCEQvF2=	M2P4VHNCVkeHUh?=
CGTH-W-1	NEXrfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDUbVdqUUN3ME2wMlYxPzV3IN88US=>	MXHTRW5ITVJ?
EB-3	NHn3UVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwNkGxOVMh\|ryP	MlrCV2FPT0WU
D-336MG	NX\4OoIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmr1TWM2OD1yLk[xO\|kyKM7:TR?=	NI\ySY9USU6JRWK=
LC-1F	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvQTVVLUUN3ME2wMlYzPTl{IN88US=>	NWq3NI15W0GQR1XS
MHH-NB-11	MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHYTWM2OD1yLk[zPFAyKM7:TR?=	NFjpRoFUSU6JRWK=
SK-N-FI	M2ftSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGX0bYVKSzVyPUCuOlM6OSEQvF2=	MYrTRW5ITVJ?
NCI-H69	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwNkS4O\|kh\|ryP	M3rMVHNCVkeHUh?=
SCH	M3nIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTBwNk[wNlMh\|ryP	NHWxWFdUSU6JRWK=
LS-513	Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml72TWM2OD1yLk[3NlU6KM7:TR?=	MkLKV2FPT0WU
CP67-MEL	MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVW4XVNtUUN3ME2wMlY4PTl4IN88US=>	M3L5RXNCVkeHUh?=
GCIY	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\5TWM2OD1yLkewN\|Y{KM7:TR?=	NEDOSWFUSU6JRWK=
SHP-77	M3;q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzFSlhLUUN3ME2wMlcxPzN2IN88US=>	NWfQT3ZRW0GQR1XS
EHEB	NWPObpVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfIV5VKUUN3ME2wMlcyQDV2IN88US=>	M4rGbHNCVkeHUh?=
D-247MG	NILhc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTHV4lSUUN3ME2wMlc{OjN{IN88US=>	M1XST3NCVkeHUh?=
Raji	NXfTNZoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTLTWM2OD1yLke0PVg6KM7:TR?=	Ml\ZV2FPT0WU
MPP-89	MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\aRW1KSzVyPUCuO\|U6PzhizszN	NXziTHF5W0GQR1XS
EKVX	NWjSWZVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTBwN{mwO\|Mh\|ryP	MXTTRW5ITVJ?
HCC2218	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTBwN{mxN\|Eh\|ryP	Mn;CV2FPT0WU
KNS-81-FD	NHzHSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nhc2lEPTB;MD64NVAyOSEQvF2=	MWrTRW5ITVJ?
HCC2157	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTBwOES5OVEh\|ryP	MWnTRW5ITVJ?
BT-474	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUW0boUyUUN3ME2wMlg5QDV2IN88US=>	M1TYTXNCVkeHUh?=
NCI-H748	NFf0U\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml20TWM2OD1yLkmxNkDPxE1?	MlKyV2FPT0WU
EW-24	NFWycnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnoeYJqUUN3ME2wMlkzODB{IN88US=>	MULTRW5ITVJ?
D-263MG	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGi2W4hKSzVyPUCuPVQ2OTJizszN	Mmi4V2FPT0WU
OMC-1	NFLEfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEizSnVKSzVyPUCuPVY{PzNizszN	M13GSHNCVkeHUh?=
NCI-H2196	NGq2TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\ES2lEPTB;MD65O\|c4PyEQvF2=	NUO0bIpJW0GQR1XS
HAL-01	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jxN2lEPTB;MD65PVg4OiEQvF2=	NITZW2xUSU6JRWK=
NCI-H2107	MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2SzUmlEPTB;MT6wNVg2PCEQvF2=	M4nIV3NCVkeHUh?=
LB996-RCC	NWXtSJlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvTPYZKSzVyPUGuNFgxPTFizszN	NVLCb\|MyW0GQR1XS
NCI-H1395	NGH3TIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TVd2lEPTB;MT6xNFY4KM7:TR?=	MV\TRW5ITVJ?
CHP-126	MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHhNXVKSzVyPUGuNVYyQTlizszN	MkfCV2FPT0WU
NB69	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoH0TWM2OD1zLkK2NVQ5KM7:TR?=	M4m1V3NCVkeHUh?=
CAS-1	NVjxcJFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTFwM{SyN\|Eh\|ryP	MmnVV2FPT0WU
JVM-3	M1TiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHsTWM2OD1zLkS3PFU2KM7:TR?=	NXHiR25bW0GQR1XS
DMS-153	M1LVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3MTWM2OD1zLkW3Olc1KM7:TR?=	NHTPb5RUSU6JRWK=
SK-MEL-2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrYUFhHUUN3ME2xMlcyPzh7IN88US=>	MVvTRW5ITVJ?
NCI-H1155	NHTrWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rEU2lEPTB;MT63N\|Y4PiEQvF2=	M4ezfXNCVkeHUh?=
NCI-H1092	M2jxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\De2lEPTB;MT63OlE5OiEQvF2=	NUCwOnU2W0GQR1XS
LU-165	NYXqPXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Hyc2lEPTB;MT64OlQ4PiEQvF2=	NGnBSINUSU6JRWK=
HL-60	M4XwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHoTHdIUUN3ME2xMlk6QTB6IN88US=>	MUDTRW5ITVJ?
REH	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJwMEC1PFIh\|ryP	NULnOVhGW0GQR1XS
JVM-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJwME[xN\|Uh\|ryP	MW\TRW5ITVJ?
MN-60	M{C4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zpO2lEPTB;Mj6xO\|MxQCEQvF2=	M4foe3NCVkeHUh?=
SCC-15	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1L0NmlEPTB;Mj6yNFI4KM7:TR?=	M4rz[3NCVkeHUh?=
SNU-C1	NWjkZ4R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTJwMkGzOFMh\|ryP	NXPQZ3hGW0GQR1XS
SK-MEL-1	MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXf1R3RpUUN3ME2yMlMzODR5IN88US=>	M3P4T3NCVkeHUh?=
TGW	MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTEVZJKSzVyPUKuN\|UxOjdizszN	MlzEV2FPT0WU
CA46	MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLjPYxKSzVyPUKuO\|U6PjdizszN	NWLQeFVjW0GQR1XS
NCI-H23	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ftOGlEPTB;Mj64NFc6OSEQvF2=	M1TmNnNCVkeHUh?=
MMAC-SF	MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\UcHpKSzVyPUKuPFY3OjhizszN	NWDj[W4{W0GQR1XS
NCI-H2171	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LpVmlEPTB;Mz6wN\|Q1QCEQvF2=	NFXsbYVUSU6JRWK=
A704	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\F[GlEPTB;Mz6xOFE6PCEQvF2=	NInsSpNUSU6JRWK=
DB	M2S4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTNwMkW1O\|Yh\|ryP	MVzTRW5ITVJ?
NCI-H719	NWXWZ\|BUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjLeYlKSzVyPUOuN\|A{QDRizszN	MV;TRW5ITVJ?
MC-CAR	M1\zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjDZmtKSzVyPUOuOVQ5OTdizszN	NInseoNUSU6JRWK=
SIMA	M37XeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTNwNUi0NVYh\|ryP	MkK3V2FPT0WU
SW872	NVjzc2Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDxVGpKSzVyPUOuO\|gyODFizszN	NWfaUFRmW0GQR1XS
HCC1187	M{DQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\COFNKSzVyPUOuO\|g{OTVizszN	NVLDbXpDW0GQR1XS
EW-13	Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTNwOEO0NVch\|ryP	NH2wbG1USU6JRWK=
NCI-SNU-1	NHmxR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljmTWM2OD12LkKxPVk6KM7:TR?=	NEjKW2pUSU6JRWK=
NCI-H226	MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVu1NpZmUUN3ME20MlM{PjB4IN88US=>	M{\FOXNCVkeHUh?=
RPMI-8866	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;GdnhKSzVyPUSuN\|YxOjlizszN	NUXwdlVRW0GQR1XS
OCI-AML2	M4OxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGS1S5dKSzVyPUSuOVUzOyEQvF2=	Mon1V2FPT0WU
LU-65	NW\5[W5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTRwOUOwN\|Mh\|ryP	Mmm2V2FPT0WU
SK-N-DZ	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLVc2pKSzVyPUWuOlM1PjVizszN	NIDidIpUSU6JRWK=
NB14	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzienpKSzVyPUWuPVcyOzVizszN	MWnTRW5ITVJ?
COLO-829	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjGNVFKSzVyPU[uN\|M{PTlizszN	Ml3lV2FPT0WU
MHH-CALL-2	MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUWyVYtXUUN3ME22MlUyPTB6IN88US=>	MYHTRW5ITVJ?
NCI-H1770	NIfyclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHw[2JKSzVyPU[uOlY6ODRizszN	NVe5cYVEW0GQR1XS
ECC4	M3\vXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTZwOEKxO\|kh\|ryP	MXnTRW5ITVJ?
A498	Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfOTWM2OD14Lki3NVkzKM7:TR?=	NWXI[3FjW0GQR1XS
DMS-79	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHUSHFbUUN3ME23MlA1PTF{IN88US=>	NHvCZolUSU6JRWK=
P30-OHK	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWX2bGVWUUN3ME23MlIyQTB4IN88US=>	M3i4UXNCVkeHUh?=
D-502MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXVVnkyUUN3ME23Mlk5OzZizszN	NEn6RYRUSU6JRWK=
RCC10RGB	NIHrfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHBU2gxUUN3ME24MlA3OjhizszN	M2O5RXNCVkeHUh?=
U-698-M	MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTMTWM2OD16LkK5NlI3KM7:TR?=	NFnzUIFUSU6JRWK=
BB49-HNC	NF\zVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTFTWM2OD17LkSyNlY2KM7:TR?=	NHP0RYlUSU6JRWK=
ES1	NX;Ec2lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nGe2lEPTB;OT62PFk2PiEQvF2=	M{T1T3NCVkeHUh?=
MFM-223	NVXPb\|lPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXNfYtKUUN3ME2xNE46QTJ5IN88US=>	NF;FO4RUSU6JRWK=
C2BBe1	NX;ITmJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLaZ3F6UUN3ME2xNU4{PTJ\|IN88US=>	MlvZV2FPT0WU
EB2	MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\WTWM2OD1zMj62PFgyKM7:TR?=	M3nIZnNCVkeHUh?=
C8166	NEnaPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTF\|LkizNFMh\|ryP	NEPmPZpUSU6JRWK=
ES3	M160WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnXNGxuUUN3ME2xN{46QTd5IN88US=>	NVSxR5JYW0GQR1XS
NCI-H1650	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVy2cZh[UUN3ME2xOk4{PzZ3IN88US=>	M{X5PXNCVkeHUh?=
Mo-T	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLHTWM2OD1zNz60NFI6KM7:TR?=	NFvVeGNUSU6JRWK=
NB7	NGO0XnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTF5Lke0Olch\|ryP	MXTTRW5ITVJ?
ES7	M1;3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PM[mlEPTB;MUmuOVUxPyEQvF2=	NUPKUFl[W0GQR1XS
ES5	NY\BNnpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvYOpRMUUN3ME2yNU44PjdzIN88US=>	NH;jSVFUSU6JRWK=
MSTO-211H	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fsNmlEPTB;MkGuPFg2QCEQvF2=	NISwSVNUSU6JRWK=
U-87-MG	NXHJNpZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYraWJJQUUN3ME2yOU4yQTZ4IN88US=>	MYjTRW5ITVJ?
THP-1	NHrsZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HCSmlEPTB;MkmuO\|IxOSEQvF2=	MoDLV2FPT0WU
NB10	NIjKdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTNyLkK2PVQh\|ryP	MoXoV2FPT0WU
NH-12	NXHnSIdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1P3T2lEPTB;M{OuNlAyPyEQvF2=	MlLFV2FPT0WU
COLO-824	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfUO4JKSzVyPUO0MlExODZizszN	MnTWV2FPT0WU
SKM-1	NInSfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF32bXFKSzVyPUO3Mlg1OjJizszN	NV7wNpk2W0GQR1XS
NCI-H1838	M4H0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfQTWM2OD1\|OD6zO\|k4KM7:TR?=	NUPpR\|NCW0GQR1XS
RL	M2LSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHZTWM2OD1\|OT6yOFc4KM7:TR?=	MnfBV2FPT0WU
COLO-800	M1vkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2myO2lEPTB;NECuNFc4OyEQvF2=	Ml7pV2FPT0WU
KG-1	NFu1cllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUS4bnJQUUN3ME20NE45QTV3IN88US=>	NFv6O5VUSU6JRWK=
TUR	M2P5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLmTWM2OD12MT62N\|k6KM7:TR?=	MmTmV2FPT0WU
LNCaP-Clone-FGC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\zb41KSzVyPUSxMlkxOTdizszN	NYX0[W5tW0GQR1XS
NCI-H322M	M3Kxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\VTWM2OD12Mj61PVg1KM7:TR?=	MknYV2FPT0WU
LNCaP	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fmc2lEPTB;OUGuN{BvVQ>?	NXXBSVBwOjV3MEWxO\|Q>
C4-2	M4rFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrqfndKSzVyPUigcm0>	MoTYNlU2ODVzN{S=
JURKAT	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3LOTVI1KGh?		MWjJR\|UxRTRzNj62OkBvVQ>?	MYqyOFUyQTl7NR?=
MOLT-4	Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYmyOEBp		M3jXWWlEPTB;Mki1N{42KG6P	NWnrSY86OjR3MUm5PVU>
REH	NFiwfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX:yOEBp		Mn;GTWM2OD1{OEeuOlghdk1?	MofqNlQ2OTl7OUW=
NALM-6	M1j6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXvJ[oF2OjRiaB?=		NGLlNmFKSzVyPUO0N\|MxKG6P	MXuyOFUyQTl7NR?=
RS 4;11	M1PTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF\MS2wzPCCq		M2PnNmlEPTB;NUG5MlA2KG6P	NIP2S\|AzPDVzOUm5OS=>
697	NIrxcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4Hk[FI1KGh?		MkCzTWM2OD1{MUC3MlEhdk1?	M4KwRlI1PTF7OUm1
SIL-ALL	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWmyOEBp		MWfJR\|UxRTF7OT63O{BvVQ>?	NG[5RoYzPDVzOUm5OS=>
CEM	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmrjNlQhcA>?		MXPJR\|UxRTV{LkG4JI5O	MXuyOFUyQTl7NR?=
P12	M4TPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NG\WNGYzPCCq		NYm3WlZKUUN3ME2zPU4zPyCwTR?=	NXHYSYIyOjR3MUm5PVU>
NALM-16	MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFPWXpgzPCCq		M2m0S2lEPTB;OU[uNlghdk1?	MUiyOFUyQTl7NR?=
JURKAT	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXjXd3pnPDhiaB?=		MULJR\|UxRTF2Lki0JI5O	NX;O[4g6OjR3MUm5PVU>
MOLT-4	NIH3fnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUH4boluPDhiaB?=		M{fhfWlEPTB;Mk[uOkBvVQ>?	NHTlT4YzPDVzOUm5OS=>
REH	M1HHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIf6Z\|E1QCCq		MoXiTWM2OD12ND63NUBvVQ>?	M2XCTVI1PTF7OUm1
NALM-6	MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYi0PEBp		M4n2UWlEPTB;MkOuNlYhdk1?	M3rnc\|I1PTF7OUm1
RS 4;11	MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml3xOFghcA>?		M1\nWmlEPTB;MU[0MlI5KG6P	NXnjdpRFOjR3MUm5PVU>
697	NEPTW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXizSGdSPDhiaB?=		M3jSbGlEPTB;M{C1MlMhdk1?	MWCyOFUyQTl7NR?=
SIL-ALL	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHf5PGU1QCCq		Mln5TWM2OD15ND62NkBvVQ>?	MYOyOFUyQTl7NR?=
CEM	M1vpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYm0PEBp		MlPJTWM2OD1{ND61OUBvVQ>?	NWrQeHh5OjR3MUm5PVU>
P12	NYjEOVlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmDXOFghcA>?		MVjJR\|UxRTF6LkS2JI5O	MXuyOFUyQTl7NR?=
NALM-16	NGizdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVy0PEBp		NETTRZdKSzVyPU[zMlI1KG6P	MlvONlQ2OTl7OUW=
JURKAT	NVX6XVhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3v5c\|czKGh?		MnrETWM2OD1\|Lk[1JI5O	MoeyNlQ2OTl7OUW=
MOLT-4	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH;TU\|g4OiCq		MV7JR\|UxRTdwM{mgcm0>	MX[yOFUyQTl7NR?=
REH	NUfnPFA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYnQPWVrPzJiaB?=		MnzTTWM2OD1zNj6wNUBvVQ>?	Mn7HNlQ2OTl7OUW=
NALM-6	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX[3NkBp		NFnYS4dKSzVyPUGuO\|ghdk1?	NVTleZpNOjR3MUm5PVU>
RS 4;11	NX;RS5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYi3NkBp		M2LCT2lEPTB;ND6zPEBvVQ>?	M1mxb\|I1PTF7OUm1
697	MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEPmcZc4OiCq		M3TrZmlEPTB;N{SuNlghdk1?	MlK4NlQ2OTl7OUW=
SIL-ALL	M2XoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVq3NkBp		NVjEW4M4UUN3ME23MlIhdk1?	NUO0bXZZOjR3MUm5PVU>
CEM	MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUfjZ4FIPzJiaB?=		NEHwOlBKSzVyPUWuOFIhdk1?	MUCyOFUyQTl7NR?=
P12	NFvlW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGjicJM4OiCq		M{jQ[GlEPTB;Nj6zO{BvVQ>?	M1XBPFI1PTF7OUm1
NALM-16	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXHuNWp6PzJiaB?=		MkfDTWM2OD15Nz63N{BvVQ>?	M1\mSFI1PTF7OUm1
Y79	MV3BdI9xfG:\|aYOgRZN{[Xl?	NVviWnhmOS13MDDuUS=>	NVfsepg6OTJxMkSgbC=>	NXXWUIZ[TE2VTx?=	M1HDZolv\HWlZXSgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDIWC=>	MnTPNlQ{PjZ4NkW=
WER-Rb-1	NG\oUVJCeG:ydH;zbZMhSXO\|YYm=	NEnJU2IyNTVyIH7N	MU[xNk8zPCCq	MkPtSG1UVw>?	NXTWVGxPcW6mdXPl[EBieG:ydH;zbZMhf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGhV	NInBcHAzPDN4Nk[2OS=>
G7	NYnEW3c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXi1S2t6UUN3ME2zMlMhdk1?	NVvWPGVEOjR{MES3N\|M>
G166	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXNNJFKSzVyPUeuNEBvVQ>?	NW[2cZJoOjR{MES3N\|M>
CB660	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\yOlNZUUN3ME22MlQhdk1?	M3roOFI1OjB2N{Oz
CB1117	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHlTWM2OD1zNT62JI5O	MoTnNlQzODR5M{O=
KB-3-1	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;RdZdKSzVyPUGuOFghyrFiMD61N{BvVQ>?	NYjkRVExOjN7NkK0OFU>
KB-8-5-11	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnf2TWM2OD13LkCxJOKyKDJwMEGgcm0>	NEnFWHgzOzl4MkS0OS=>
KB-C-1	NXq3dVhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTF4Lke2JOKyKDRwNUGgcm0>	M1XjXVI{QTZ{NES1
KB-V-1	M37rNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXy3fY86UUN3ME2yPFEvOjRiwsGgN\|EvPTdibl2=	M4C2NlI{QTZ{NES1
OVCAR-8	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1L0VmlEPTB;Nz6xPUDDuSB\|Lk[wJI5O	NHXXVlQzOzl4MkS0OS=>
NCI-ADR-RES	M3H2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXEWWFKSzVyPUGyO\|MvOzBiwsGgNVkyNjJyIH7N	NF\idJkzOzl4MkS0OS=>
MCF7	M1\IOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\RfnM4UUN3ME21MlEyKMLzIEGuOFchdk1?	NFLoWYwzOzl4MkS0OS=>
MCF7-FLV1000	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTN7Mz6xPEDDuSB5ND64N{BvVQ>?	NFTiS2EzOzl4MkS0OS=>
S1	NF30cWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXpTWM2OD1{ND6zNEDDuSB2Lke1JI5O	Mly0NlM6PjJ2NEW=
S1-M1-80	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vKWWlEPTB;Mk[xMlA3KMLzIES4MlI2KG6P	MmrONlM6PjJ2NEW=
CORL-23/P	NVvhXIptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXmRYVKSzVyPUSuN\|ghyrFiMT6yOUBvVQ>?	MUWyN\|k3OjR2NR?=
CORL-23/R	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLXTWM2OD13LkG2JOKyKDFwOEOgcm0>	M4fTe\|I{QTZ{NES1
NIH3T3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHaT3BrUUN3ME20NE43OCEEsTC0Mlk4KG6P	MUmyN\|k3OjR2NR?=
NIH3T3-G185	M2X3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHVVVNKSzVyPUK0NVMvPDBiwsGgOFI{NjZ4IH7N	M1jUcVI{QTZ{NES1
pcDNA-HEK293	NVrSfXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;DbplPUUN3ME2yMlc2KMLzIECuOlchdk1?	MU[yN\|k3OjR2NR?=
MDR19-HEK293	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1SyR2lEPTB;OEWuOVAhyrFiMUOuOlchdk1?	Ml\xNlM6PjJ2NEW=
R482-HEK293	MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHtTWM2OD1{NT65O{DDuSB2Lkm1JI5O	MW[yN\|k3OjR2NR?=
MRP1-HEK293	NWizS3czT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XHNGlEPTB;Mj65PUDDuSBzLkS5JI5O	NYXtNYVGOjN7NkK0OFU>
SF188	M1TmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUGxNE0yODBibl2=	MorzNlQuQTZiaB?=	NGrITYlFVVOR	MmjzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj2g[IVx\WSnboSgcYFvdmW{	NWPPPZdtOjN6OEe2OFU>
T98G	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHJZm9vOTBvMUCwJI5O	MnrYNlQuQTZiaB?=	M2LrVmROW09?	MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK=	M2\RUFI{QDh5NkS1
DU145	NHSyWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIj4ZVZFVVOR	NHnOcGRKSzVy4pk8OlAhdk1?	NWr1RWV6OjN6OES0Nlg>
LNCaP	NHH1blhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4XlVGROW09?	NIT6PW5KSzVy4pk8O\|Uhdk1?	NVTIdHpxOjN6OES0Nlg>
PC3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MW\EUXNQ	Mn;CTWM2OOLKvEG3OUBvVQ>?	M2PZO\|I{QDh2NEK4
RT4	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnzfINyUUN3ME2yO{4zOSCwTR?=	MkTTNlM4QTJ4M{m=
5637	NXvtbHZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTR3LkS3JI5O	NXLPSHMxOjN5OUK2N\|k>
T24	NXn5WohUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUCydJBOUUN3ME23PU4yOiCwTR?=	NGm2cZUzOzd7Mk[zPS=>
MCF7	MoPRSpVv[3Srb36gRZN{[Xl?	MVGxNFAhdk1?	NXrkN3lHOSCq	NV;ORm1bTE2VTx?=	NYDLTnVwemWmdXPld{B1cGViaX7keYN1cW:wIH;mxsBIemWkMT\|CpHNoczFuwrDQd\|ItyqCVZYLwbY5iOyxiYX7kxsBYcXOyMh?=	M4rZdVI{PzdyMkS0
KB-V1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTNwOUKg{txO	NVzoOnE3OjN3OUOxPVY>
Hec50co	NHH1cW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PlbGlEPTB;NTDuUS=>	Mk[1NlMyPDZ4OEe=
MDA-MB-468	Ml;SRZBweHSxc3nzJGF{e2G7	M2focFEwPS9zMDDuUS=>	MWKyOE81QC95MjDo	NUKwRlRYTE2VTx?=	MmeybY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M4\PfFI{OTR2Mkm0
MCF10A	NULTXHUzSXCxcITvd4l{KEG\|c3H5	NVfiO3NFOS93L{GwJI5O	MYKyOE81QC95MjDo	MkToSG1UVw>?	NXSzeGFEcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NFnhVGozOzF2NEK5OC=>
Huh-7	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTaNU8yOC9zMECvNVAxOCCwTR?=	M3T5V\|Q5KGh?		MlfW[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBld3OnLXTldIVv\GWwdHz5	MlLvNlI4PDV3OEe=
Daoy	M3;0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHPTG1ZOS56N{WtNlQxKG6P	M3nTcVczKGh?	NW\tNJNRTE2VTx?=	Ml;CTWM2OD13IH7N	NVXUe\|JtOjJ\|OUCyO\|k>
ONS-76	MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnj1NU45PzVvMkSwJI5O	NVLEfZhnPzJiaB?=	NFrpR5FFVVOR	NYDyfGpqUUN3ME23MlUhdk1?	MWGyNlM6ODJ5OR?=
SUM 149	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFH6XFgxNTFyMDDuUS=>	NIrMdXA4OiCq		MUjpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	M3LnTVIzOzB7OUO5
MDA-MB-231	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUGwMVExOCCwTR?=	M4XHWVczKGh?		NVPp[WNScW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NYrOZ3J3OjJ\|MEm5N\|k>
HR5	NV3OcWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVewMVExOCCwTR?=	MVy3NkBp		MnfBbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	Mo\UNlI{ODl7M{m=
BT-474-M1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\oNE0yODBibl2=	M2Pa[VczKGh?		NXnRS3E4cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	MXSyNlMxQTl\|OR?=
AU565	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6wMVExOCCwTR?=	Ml71O\|IhcA>?		MYjpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	M2LkZ\|IzOzB7OUO5
T47D	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXRPHQxNTFyMDDuUS=>	MonlO\|IhcA>?		NIXicmRqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	Mmm5NlI{ODl7M{m=
MCF7	M{\PVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnhTllOOC1zMECgcm0>	M2ri[\|czKGh?		NU[xPHRlcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	M1TQRVIzOzB7OUO5
HCT116p53(+/+)	M{D0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWWxNE0yODByIH7N	M37uNlI1NzR6IHi=		NWjYfXR5cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?	MUeyNlI3OjF5MR?=
HCT116p53(-/-)	M1Hnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYCxNE0yODByIH7N	MYWyOE81QCCq		NXHFXY5ocW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?	MUiyNlI3OjF5MR?=
HeLa	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:1XFExNTFyMDDuUS=>	NWLsRXh7PDhiaB?=	NHTSZ5RFVVOR	MoTITWM2OD13Mj65JI5O	NHSxeWszOjB6MEKzOS=>
HeLa	NILURpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6xNE0yODBibl2=	MmnMO\|IhcA>?	MmHTSG1UVw>?	NGe3VXdKSzVyPUWwMlUhdk1?	NYXrV\|BCOjJyOECyN\|U>
GBC	MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlrtO\|IhcA>?		NFnO[mFKSzVyPUG0Mlc5KG6P	MYKyNVk3PTd\|OR?=
GB-CL-1	NYPQTHp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mmq1O\|IhcA>?		MXrJR\|UxRTVwMkKgcm0>	MXyyNVk3PTd\|OR?=
Mz-ChA-2	MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3Pl[lczKGh?		NIjyNnZKSzVyPUOuN\|Ehdk1?	M4fIOFIyQTZ3N{O5
TGBC1-TKB	NIXyZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1H5T\|E1PCCq		MU\JR\|UxRTZwN{Kgcm0>	MYqyNVk3PTd\|OR?=
Wittier	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4DrXFczKGh?		MlLHTWM2OD1\|LkK2JI5O	NYf1TY5[OjF7NkW3N\|k>
H-1	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1zFeVczKGh?		MV;JR\|UxRTlwNUSgcm0>	MlKxNlE6PjV5M{m=
HuH-28	NGTQc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mor0O\|IhcA>?		NXS1VGVDUUN3ME2xNU4yQSCwTR?=	MorZNlE6PjV5M{m=
NEC	M{j4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{PZfFczKGh?		NFH4OFlKSzVyPUmuPVghdk1?	M4PHdlIyQTZ3N{O5
REB	M3LTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmXKO\|IhcA>?		MUnJR\|UxRTF\|LkWxJI5O	MXyyNVk3PTd\|OR?=
CC-LP-1	M2DZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2PCT\|czKGh?		M{XKNGlEPTB;NT64OEBvVQ>?	NW\5XG82OjF7NkW3N\|k>
CC-SW-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXq3NkBp		NYjyXndpUUN3ME25MlU2KG6P	MUOyNVk3PTd\|OR?=
EGI-1	NWfXe3BkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmHPO\|IhcA>?		MVLJR\|UxRTFyLkeyJI5O	MmTzNlE6PjV5M{m=
Sk-ChA-1	Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NU\2TVU2PzJiaB?=		NUnzbJV{UUN3ME2xO{4zKG6P	MX6yNVk3PTd\|OR?=
TFK-1	NUHSOoU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3;5PFczKGh?		MlnHTWM2OD1zMz60OUBvVQ>?	MY[yNVk3PTd\|OR?=
786-O	M324VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PnOlUuQDBibl2=	MV25OkBp	NHTSUZVJS2x?	MWjzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	MYeyNVY1OjN5NB?=
A498	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHKV25zPS16MDDuUS=>	M4LteVk3KGh?	MWHIR4w>	M{jWTpN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	M1XTWFIyPjR{M{e0
ACHN	NIn0fWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfVeIxCPS16MDDuUS=>	M2TFWFk3KGh?	Mof3TGNt	NXnKeodYe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MVOyNVY1OjN5NB?=
Caki-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFH5fHQ2NThyIH7N	MXy5OkBp	NUfhSHV1UEOu	MV3zeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	MVyyNVY1OjN5NB?=
SN12C	M1LvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXUWpFMPS16MDDuUS=>	M2f6c\|k3KGh?	NX:2[G1TUEOu	M2f6UpN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	MY[yNVY1OjN5NB?=
HMC-1.1	Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\BNU0yODByIH7N	M1;2TFczKGh?		NWTsbpk2cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n	NX3r[lhGOjF{NEKxPFk>
HMC-1.2	NYmzRopZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDkNU0yODByIH7N	MVO3NkBp		NWXwdmRScW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n	M2qwfVIyOjR{MUi5
C2	MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HMclEuOTByMDDuUS=>	MXG3NkBp		M1T0bolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>?	NYK3OIJUOjF{NEKxPFk>
CHP-212	MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV[xMVEzPSCwTR?=	M{PzdVI1NTF{MDDo		NX7VcG5xcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	MkjLNlEyPjl{NEK=
IMR-32	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HrSFEuOTJ3IH7N	MkDONlQuOTJyIHi=		NEnHdpdqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NYPMZYh5OjFzNkmyOFI>
Kelly	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\tPJIxOS1zMkWgcm0>	NVTvXmR3OjRvMUKwJIg>		Ml71bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	MnfVNlEyPjl{NEK=
SH-EP	M3;nOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjteHgyNTF{NTDuUS=>	MmrQNlQuOTJyIHi=		M4DmdolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	NGXIb3kzOTF4OUK0Ni=>
SH-SY5Y	NIXBcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XuclEuOTJ3IH7N	MYSyOE0yOjBiaB?=		MXnpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	MUmyNVE3QTJ2Mh?=
SK-N-AS	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\JR\|EuOTJ3IH7N	NVfoVJdjOjRvMUKwJIg>		MW\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	MmTENlEyPjl{NEK=
SK-N-BE	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH1NU0yOjVibl2=	MmS4NlQuOTJyIHi=		MVHpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	NY[1fW1qOjFzNkmyOFI>
KG1	NYnweINDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TMTVEwOTBxMUCwJI5O	M4DlSFczKGh?	MYrEUXNQ	NXexS3RucW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	NYXwTWo5OTl2NUizOVg>
U937	NF6xW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXUcJoyNzFyL{GwNEBvVQ>?	NULtb\|ZoPzJiaB?=	MkPKSG1UVw>?	MVfpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	NEL5T4oyQTR3OEO1PC=>
CAL62	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEn6UFkxNjFvMUCwJI5O	NF\WbHI4OiCq	MVXEUXNQ	NHLm[FdGSzVyPUGuOEBvVQ>?	M1K1dlE6OjJ\|NUWz
OCUT-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fBUFAvOS1zMECgcm0>	M3G1R\|czKGh?	M1\o[2ROW09?	MmfvSWM2OD1{LkOgcm0>	NYDKNnJ[OTl{MkO1OVM>
8505C	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFP4cGsxNjFvMUCwJI5O	MWC3NkBp	MkDmSG1UVw>?	M1LlXmVEPTB;Mz6yJI5O	M2ToSFE6OjJ\|NUWz
ACT-1	NIXlZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfPR3NmOC5zLUGwNEBvVQ>?	MnTTO\|IhcA>?	NEDmbVRFVVOR	M2ruWWVEPTB;NT60JI5O	M2S1[FE6OjJ\|NUWz
SW1736	NVPQbJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TVOFAvOS1zMECgcm0>	MYO3NkBp	NIPsbJpFVVOR	MUXFR\|UxRTVwNjDuUS=>	NF;VdW4yQTJ{M{W1Ny=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

In vivo

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Plk1 in vitro kinase assay: Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:^[1]	- Collapse Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc. Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 24 and 72 hours Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BomTac:NMRI-Foxn1^nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells Dosages: ~50 mg/kg Administration: Injection i.v. once or twice per week (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
	Ethanol	'100 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BI 2536 SDF

Molecular Weight	521.66
Formula	C₂₈H₃₉N₇O₃
CAS No.	755038-02-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC1N(C2CCCC2)C3=NC(=NC=C3N(C)C1=O)NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
Answer:
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Selective Plk Inhibitors

GSK461364 : Plk1-selective, K_i=2.2 nM.
Plk Inhibitor in Clinical Trial

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
Newest Plk Inhibitor

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
Calssic Plk Inhibitor

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products

SBE 13 HCl ^New

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells. Phase 3.
HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
GSK461364

GSK461364 inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.
Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.

Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.
onvansertib (NMS-P937)

onvansertib (NMS-P937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536